Phase I/II Melanoma Peptide Vaccine Trial Reports 69% Four-Year Disease-Free Survival
A randomized Phase I/II trial of a melanoma helper peptide vaccine with anti-CD27 antibody varlilumab reported 69% four-year disease-free survival in the combination arm versus 20% with vaccine alone. However, varlilumab depleted circulating CD4+ T cells, potentially limiting vaccine synergy and warranting further optimization.